Tissue	B:C0040300
-	O
selective	O
inflammation	O
in	O
the	O
oral	O
cavity	I:C0226896
of	O
the	O
rat	O
.	O

Tissue	O
-	O
selective	O
inflammation	B:C0021368
in	O
the	O
oral	O
cavity	I:C0226896
of	O
the	O
rat	O
.	O

Tissue	O
-	O
selective	O
inflammation	O
in	O
the	O
oral	B:C0226896
cavity	I:C0226896
of	O
the	O
rat	O
.	O

Tissue	O
-	O
selective	O
inflammation	O
in	O
the	O
oral	O
cavity	I:C0226896
of	O
the	O
rat	B:C0034721
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	B:C0007289
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	B:C0007289
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	B:C0007966
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	B:C0242589
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	B:C0034716
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	B:C0001563
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	B:C0243095
stimulus	O
in	O
the	O
orofacial	O
region	I:C2827582
.	O

In	O
the	O
current	O
study	O
,	O
carrageenan	O
(	O
carrageenan	O
;	O
100-1000	O
μg/site	O
)	O
was	O
injected	O
intraorally	O
in	O
the	O
cheeks	O
of	O
Holtzman	O
or	O
Wistar	O
rats	I:C0034716
to	O
evaluate	O
the	O
consequences	O
of	O
administration	O
of	O
a	O
non-immunogenic	O
stimulus	O
in	O
the	O
orofacial	B:C2827582
region	I:C2827582
.	O

Subsequent	O
inflammation	B:C0021368
was	O
measured	O
as	O
oedema	O
(	O
increased	O
thickness	I:C0277948
of	O
the	O
cheek	O
wall	I:C0007966
using	O
digital	O
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	O
injected	O
with	O
saline	O
.	O

Subsequent	O
inflammation	O
was	O
measured	O
as	O
oedema	B:C0013604
(	O
increased	O
thickness	I:C0277948
of	O
the	O
cheek	O
wall	I:C0007966
using	O
digital	O
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	O
injected	O
with	O
saline	O
.	O

Subsequent	O
inflammation	O
was	O
measured	O
as	O
oedema	O
(	O
increased	B:C0277948
thickness	I:C0277948
of	O
the	O
cheek	O
wall	I:C0007966
using	O
digital	O
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	O
injected	O
with	O
saline	O
.	O

Subsequent	O
inflammation	O
was	O
measured	O
as	O
oedema	O
(	O
increased	O
thickness	I:C0277948
of	O
the	O
cheek	B:C0007966
wall	I:C0007966
using	O
digital	O
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	O
injected	O
with	O
saline	O
.	O

Subsequent	O
inflammation	O
was	O
measured	O
as	O
oedema	O
(	O
increased	O
thickness	I:C0277948
of	O
the	O
cheek	O
wall	I:C0007966
using	O
digital	B:C0175720
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	O
injected	O
with	O
saline	O
.	O

Subsequent	O
inflammation	O
was	O
measured	O
as	O
oedema	O
(	O
increased	O
thickness	I:C0277948
of	O
the	O
cheek	O
wall	I:C0007966
using	O
digital	O
calipers	I:C0175720
)	O
,	O
relative	O
to	O
the	O
other	O
cheek	B:C0007966
injected	O
with	O
saline	O
.	O

Oedema	B:C0013604
formation	O
and	O
tissue	O
collection	O
for	O
histopathological	O
studies	I:C0677043
were	O
assessed	O
at	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
,	O
120	O
and	O
144	O
h	O
after	O
injection	O
.	O

Oedema	O
formation	O
and	O
tissue	B:C0040300
collection	O
for	O
histopathological	O
studies	I:C0677043
were	O
assessed	O
at	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
,	O
120	O
and	O
144	O
h	O
after	O
injection	O
.	O

Oedema	O
formation	O
and	O
tissue	O
collection	O
for	O
histopathological	B:C0677043
studies	I:C0677043
were	O
assessed	O
at	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
,	O
120	O
and	O
144	O
h	O
after	O
injection	O
.	O

Oedema	O
formation	O
and	O
tissue	O
collection	O
for	O
histopathological	O
studies	I:C0677043
were	O
assessed	O
at	O
0.5	O
,	O
1	O
,	O
2	O
,	O
3	O
,	O
4	O
,	O
6	O
,	O
24	O
,	O
48	O
,	O
72	O
,	O
96	O
,	O
120	O
and	O
144	O
h	O
after	O
injection	B:C0021485
.	O

In	O
parallel	O
,	O
other	O
groups	O
of	O
rats	B:C0034721
were	O
injected	O
with	O
carrageenan	O
in	O
the	O
hind	O
paw	I:C3853547
,	O
to	O
provide	O
a	O
reference	O
response	O
.	O

In	O
parallel	O
,	O
other	O
groups	O
of	O
rats	O
were	O
injected	O
with	O
carrageenan	B:C0007289
in	O
the	O
hind	O
paw	I:C3853547
,	O
to	O
provide	O
a	O
reference	O
response	O
.	O

In	O
parallel	O
,	O
other	O
groups	O
of	O
rats	O
were	O
injected	O
with	O
carrageenan	O
in	O
the	O
hind	B:C3853547
paw	I:C3853547
,	O
to	O
provide	O
a	O
reference	O
response	O
.	O

The	O
inhibitor	B:C0243077
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	B:C1157324
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	B:C0021246
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	B:C0162816
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	B:C0162757
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	B:C3543440
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	O
.	O

The	O
inhibitor	O
of	O
prostaglandin	O
biosynthesis	I:C1157324
,	O
indomethacin	O
,	O
and	O
antagonists	O
of	I:C0162816
histamine	I:C0162816
,	O
serotonin	O
and	O
NK1	O
receptors	I:C3543440
were	O
injected	O
s.c.	O
,	O
0.5	O
h	O
before	O
carrageenan	B:C0007289
.	O

carrageenan	B:C0007289
induced	O
a	O
dose	O
-	O
related	O
oedema	O
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	O
induced	O
in	O
rat	O
paws	O
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

carrageenan	O
induced	O
a	O
dose	O
-	O
related	O
oedema	B:C0013604
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	O
induced	O
in	O
rat	O
paws	O
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

carrageenan	O
induced	O
a	O
dose	O
-	O
related	O
oedema	O
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	B:C0013604
induced	O
in	O
rat	O
paws	O
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

carrageenan	O
induced	O
a	O
dose	O
-	O
related	O
oedema	O
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	O
induced	O
in	O
rat	B:C0034721
paws	O
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

carrageenan	O
induced	O
a	O
dose	O
-	O
related	O
oedema	O
more	O
rapidly	O
from	O
0	O
to	O
2	O
h	O
which	O
lasted	O
for	O
at	O
least	O
72	O
h	O
,	O
showing	O
a	O
biphasic	O
profile	O
(	O
peak	O
at	O
2	O
and	O
24	O
h	O
)	O
,	O
compared	O
with	O
the	O
monophasic	O
oedema	O
induced	O
in	O
rat	O
paws	B:C0687080
(	O
maximal	O
duration	O
of	O
24	O
h	O
)	O
.	O

Histopathological	B:C0677043
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	B:C0936012
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	B:C0007289
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	B:C0007966
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	B:C0013604
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	B:C0023516
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	B:C1622891
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	B:C1334962
and	O
mononuclear	O
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histopathological	O
analysis	O
of	O
the	O
carrageenan	O
-	O
injected	O
cheek	O
revealed	O
oedema	O
formation	O
with	O
little	O
leukocyte	O
recruitment	O
at	O
1	O
-	O
3	O
h	O
,	O
mast	O
cell	I:C1622891
degranulation	I:C1622891
at	O
6	O
h	O
,	O
and	O
a	O
mixed	O
polymorphonuclear	O
and	O
mononuclear	B:C3550052
cell	I:C3550052
infiltrate	I:C3550052
by	O
24	O
h	O
.	O

Histamine	B:C0162816
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	B:C0162757
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	B:C0021246
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	B:C3543440
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	B:C0007966
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	B:C0013604
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	O
.	O

Histamine	O
and	O
serotonin	O
antagonists	I:C0162757
and	O
indomethacin	O
,	O
but	O
not	O
the	O
NK1	O
antagonist	I:C3543440
,	O
decreased	O
cheek	O
oedema	O
in	O
the	O
first	O
4	O
h	O
following	O
carrageenan	B:C0007289
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	B:C0021368
between	O
the	O
oral	O
cavity	I:C0226896
and	O
the	O
paw	O
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	O
cavity	I:C0226896
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	O
between	O
the	O
oral	B:C0226896
cavity	I:C0226896
and	O
the	O
paw	O
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	O
cavity	I:C0226896
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	O
between	O
the	O
oral	O
cavity	I:C0226896
and	O
the	O
paw	B:C0687080
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	O
cavity	I:C0226896
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	O
between	O
the	O
oral	O
cavity	I:C0226896
and	O
the	O
paw	O
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	B:C0087111
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	O
cavity	I:C0226896
.	O

Taken	O
together	O
,	O
our	O
data	O
indicated	O
important	O
differences	O
in	O
the	O
pattern	O
of	O
inflammation	O
between	O
the	O
oral	O
cavity	I:C0226896
and	O
the	O
paw	O
which	O
will	O
determine	O
the	O
therapeutic	O
approach	O
to	O
the	O
treatment	O
of	O
inflammatory	O
conditions	O
in	O
the	O
oral	B:C0226896
cavity	I:C0226896
.	O

